MedTrace Logo

Next-generation Sequencing in Gastrointestinal Cancer

NCT03476057 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2018-07-02

No results posted yet for this study

Summary

Liquid biopsy has been successfully applied to the treatment and diagnosis of cancer. cfDNA has been paid more and more attention in liquid biopsy. Previous studies have shown that cfDNA can be used for predicting the efficacy of radiotherapy or chemotherapy for lung cancer, rectal cancer and esophageal cancer. It is also reported that cfDNA can be used for the evaluation of postoperative recurrence of advanced gastric cancer. However, the use of NGS to detect cfDNA in gastrointestinal tumors has not been reported. The purpose of this study is to investigate the correlation between cfDNA, cfDNA tumor buden with advanced gastrointestinal tract tumor patients, and find out prognosis gene of advanced gastrointestinal tract tumor.

Conditions

Interventions

DIAGNOSTIC_TEST

Device： NGS sequencing cfDNA

NGS sequencing cfDNA and Tumor Burden

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03476057 on ClinicalTrials.gov